Early Sjögren's Panel: SP1, PSP, CA6 Test Accuracy

If your doctor has mentioned an “Early Sjögren’s” blood panel, they are referring to a specialized test that looks for three distinct autoantibodies: salivary protein 1 (SP1), parotid secretory protein (PSP), and carbonic anhydrase 6 (CA6) ^[1]. Autoantibodies are immune system proteins that mistakenly target the body’s own tissues. While traditional tests for Sjögren’s syndrome look for the well-established ANA, SSA/Ro, and SSB/La antibodies, this newer panel searches for markers that often appear earlier in the disease process ^[1].

Why is this panel used?

Diagnosing primary Sjögren’s syndrome can be a long and frustrating process. Many people experience the classic symptoms of dry eyes, dry mouth, and profound fatigue, yet their standard autoimmune blood work comes back completely normal ^[2][3]. This is sometimes referred to as being seronegative—meaning you have the symptoms, but lack the traditional blood markers.

The Early Sjögren’s panel was developed to help identify the condition in these seronegative patients. Preliminary research suggests that testing for SP1, PSP, and CA6 may offer higher accuracy for diagnosing Sjögren’s in its earliest stages, well before the traditional markers appear in the blood ^[1]. By detecting these novel autoantibodies, doctors may be able to diagnose the condition earlier. An early diagnosis can lead to faster medical intervention, potentially improving both glandular symptoms (like dry eyes and mouth) and extra-glandular symptoms, such as joint pain and nerve issues ^[4][1].

Accuracy and Official Guidelines

While the Early Sjögren’s panel can be a helpful piece of the diagnostic puzzle, it is important to understand its current limitations. As of right now, SP1, CA6, and PSP are not included in the official classification criteria for Sjögren’s syndrome established by the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) ^[5][6].

Currently, the ACR/EULAR guidelines rely heavily on the traditional anti-SSA/Ro blood test, along with objective clinical measures like salivary flow rates, eye staining tests, and lip biopsies (a minor salivary gland biopsy) to definitively confirm the disease ^[5][6].

Because these newer early markers lack validation in large, international frameworks, there is not yet a wide medical consensus on their routine clinical use ^[7][8][9]. A major reason for this caution is the risk of false positives—these early markers can sometimes appear in the blood of people who do not actually have Sjögren’s syndrome ^[7]. Medical guidelines require highly specific tests to prevent misdiagnosis and ensure patients aren’t given unnecessary immune-suppressing medications ^[8].

What This Means for You

• It is not stand-alone proof: A positive result on the Early Sjögren’s panel can point your doctor in the right direction, but it is not accepted by major rheumatology guidelines as stand-alone proof of the disease ^[9][10].
• Further testing is often required: If you have a positive early panel but negative traditional markers, your rheumatologist will likely recommend additional testing, such as a lip biopsy or specialized eye exams, to formally confirm your diagnosis ^[6].
• What if both panels are negative? Even if both your traditional blood markers and the Early Sjögren’s panel are completely negative, it is still possible to have Sjögren’s syndrome ^[11]. In these cases, doctors rely on your clinical symptoms and objective tests like the lip biopsy to reach a diagnosis ^[11].
• Practical considerations: Because this panel is not universally adopted, it often must be sent to specialized commercial reference labs rather than run at your local hospital lab. Additionally, you may want to check with your insurance provider to ensure the test is covered, as some companies may not pay for diagnostics that are not yet part of the official ACR/EULAR criteria.